Biohaven Pharmaceutical Holding Company Ltd. BHVN 深 沪
已收盘 08-01 16:00:00 美东时间
14.71
-0.390
-2.58%
华盛通- 最 高15.09
- 今 开14.99
- 成交量 246.30万股
- 最 低 14.295
- 昨 收 15.10
- 总市值 15.00亿
- 52周最高 55.70
- 市盈率 静 --
- 换手率 2.41%
- 52周最低 12.79
- 委 比 93.78%
- 总股本 1.02亿
- 历史最高 152.56
- 量 比 0.82
- 振 幅 5.26%
- 历史最低 7.10
- 每 手 1
- 风险率 12.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | FDA人事变动或缓解监管压力，REPL飙涨超101%；SUPX大涨44%
FDA人事变动或缓解监管压力，REPL飙涨超101%；推出英伟达Blackwell架构AI服务器，SUPX大涨44%>>
07-31 14:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
07-31 01:07
Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 0.1% on Wednes...
07-30 22:47
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) have oppo...
07-29 00:00
单月超20亿美元，Biotech行业融资规模重返疫情前水平
转自：新康界 今年5月，美国及欧洲的生物医药行业共发生23起融资事件，融资规模达20.2亿美元（约143.03亿人民币），环比增幅达59.18%，其中值得关注的...
06-30 17:32
美股大行评级 | 潜在涨幅261.01%！瑞穗上调Immuneering目标价至10美元，维持"跑赢大市"评级
康托·菲茨杰拉德：维持Meta Platforms(META)"超配"评级，目标价从676美元升至807美元
06-19 09:23
JP Morgan Maintains Overweight on Biohaven, Lowers Price Target to $55
JP Morgan analyst Tessa Romero maintains Biohaven (NYSE:BHVN) with a Overweight and lowers the price target from $68 to $55.
06-18 20:33
Bexorg Announces Multi-Program Research Collaboration With Biohaven To Identify, De-Risk, And Advance Next-Generation Therapies For CNS Disorders
Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd.
06-11 02:01
Biohaven Initiates Global Phase 2/3 Study Of First-In-Clinic, Orally-Administered, Brain-Penetrant, And Highly Selective TYK2/JAK1 Inhibitor, BHV-8000, For PD Treatment
BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysregulation that drives
05-29 19:03
Biohaven Issues Update And Preliminary Clinical Data From Oncology Development Programs At 2025 R&D Day
BHV-1510, a highly differentiated Trop2 ADC incorporating the proprietary TopoIx payload, demonstrates early clinical activity and favorable safety profile in Phase 1 study as a monotherapy and in combination with
05-28 19:32
